Mesoblast's (ASX:MSB) cell therapy showed improved outcomes in heart disease patients based on data from a phase 3 trial, according to a Tuesday filing with the Australian bourse.
The randomized controlled study, named DREAM-HF, showed that a single intramyocardial injection of Revascor-branded allogeneic cell therapy, rexlemestrocel-L, showed an improvement in the survival of high-risk patients with ischemic heart failure and inflammation, the filing said.
Results from the trial were published in November in the peer-reviewed European Journal of Heart Failure, the filing added.
The company's shares were up almost 2% in recent Tuesday trade.
Price (AUD): $1.83, Change: $+0.03, Percent Change: +1.50%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.